MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, aimed at treating venous leg ulcers (VLUs). With a market capitalization of $186 million and a strong balance sheet showing more cash than debt, the company is well-positioned to advance this clinical program. The study, known as the VALUE trial, is a global endeavor set to evaluate the safety and effectiveness of EscharEx in debridement and aiding wound closure.
The VALUE trial is a double-blind, placebo-controlled study that will span across 40 sites in the United States and Europe. It is set to enroll 216 patients who will be randomized to receive either EscharEx or a placebo. Participants will undergo up to eight applications of the treatment over a two-week period, followed by ten weeks of standardized wound management. The primary endpoints of the trial will be the incidence of complete debridement and complete wound closure, with secondary endpoints including the incidence of complete granulation tissue and time to wound closure, among others.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.